Abstract��OBJECTIVE To report a clinical case and review the therapy of renal anemia in children with EPO-�� non-response to provide ideas on optimization of dosing regimens and new ways of clinical practice. METHODS One case of renal anemia was described and analyzed, and relevant literature was accessed and reviewed. RESULTS The level of hemoglobin increased to 100 g��L-1 and the clinical symptoms were alleviated after transfering to EPO-�� from EPO-��. CONCLUSION For pediatric patients with chronic renal anemia, EPO-�� instead of EPO-�� is effective.
������, ����, ����, ���, ����ƽ. �����˴ٺ���-��������Ч������ƶѪ����Ӧ��EPO-�²����������[J]. �й�ҩѧ��־, 2016, 51(11): 948-952.
CHEN Ting-ting, LI Qin, SHEN Qian, XU Hong, LI Zhi-ping. Erythropoietin-�� in Chronical Kidney Diseases Children Non-responsive to EPO-��:A Case Report and Review of the Literature. Chinese Pharmaceutical Journal, 2016, 51(11): 948-952.
MATUSZKIEWICZ-ROWINSKA J. New European best practice guidelines for the management of anemia in patients with chronic renal failure[J]. Pol Arch Med Wewn, 2005, 113(4):387-394.
[2]
LEVIN A, STEVENS P E, BILOUS R W, et al. Kidney disease:improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int Suppl, 2013, 3(1):1-150.
[3]
TRIOLO G. Guidelines for the treatment of anemia in chronic renal failure[J]. G Ital Nefrol, 2003,20(suppl 24):s61-s82.
[4]
NAPRTCS. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS), 2004 Annual Report. [EB/OL]. NAPRTCS, 2004 [2016-05-31] http://web. emmes.com/study/ped/annlrept/annlrept, 2004. pdf.
[5]
BAMGBOLA O F. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease[J]. Kidney Int, 2011, 80(5):464-474.
[6]
KDOQI, NATIONAL KIDNEY FOUNDATION. KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease [J]. Am J Kidney Dis, 2006, 47 (5 suppl 3):11-145.
[7]
PORT R E, MEHLS O. Erythropoietin dosing in children with chronic kidney disease:based on body size or on hemoglobin deficit?[J]. Pediatr Nephrol, 2009, 24(3):435.
[8]
YANG G, CHENG Q, LIU S, et al. Pure red cell aplasia due to anti-erythropoietin antibodies or isoniazid? A case report from a 94-year-old man[J]. Aging Clin Exp Res, 2015, 27(4):561-562.
[9]
AOKI K, ONO Y, TABATA S, et al. Successful treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with low-dose prednisolone[J]. Int J Hematol, 2013, 97(2):272-274.
[10]
SHIN S K, PACK S P, OH J, et al. Anti-erythropoietin and anti-thrombopoietin antibodies induced after administration of recombinant human erythropoietin[J]. Int Immunopharmacol, 2011, 11(12):2237-2241.
[11]
CHEN C Y,SHENG X Y,LIANG Y,et al. Pharmacists�� participation in the management of chronic kidney disease:a systematic review[J]. Chin Pharm J(�й�ҩѧ��־),2015,50(1):80-84.
[12]
BABITT J L, LIN H Y . Mechanisms of Anemia in CKD[J]. J Am Soc Nephrol, 2012, 23(10):1631-1634.
[13]
ZADRAZIL J, HORAK P. Pathophysiology of anemia in chronic kidney diseases:a review[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2015,159(2):197-202.
[14]
ECKARDT K U, RATCLIFFE P J, TAN C C, et al. Age-dependent expression of the erythropoietin gene in rat liver and kidneys[J]. J Clin Invest, 1992, 89(3):753-760.
[15]
Mandarin_Anemia Guideline Summary Translation[J]. Chin J Intern Med (�л��ڿ���־), 2013,52(6):521-523.
[16]
JELKMANN W. Physiology and pharmacology of erythropoietin[J]. Transfus Med Hemother, 2013,40(5):302-309.
[17]
WV D O L, SABINO A P, FIGUEIREDO R C, et al. Inflammation and poor response to treatment with erythropoietin in chronic kidney disease[J]. Minerva Stomatol, 2015, 37(2):137-164.
[18]
GUNNELL J, YEUN J Y, DEPNER T A, et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients[J]. Am J Kidney Dis, 1999, 33(1):63-72.
[19]
RIANTHAVORN P, BOONYAPAPONG P. Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5[J]. Pediatr Nephrol, 2013, 28(8):1261-1266.
[20]
WASLEY L C, TIMONY G, MURTHA P, et al. The importance of N- and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin[J]. Blood, 1991, 77(12):2624-2632.
[21]
RAMBOD M, KOVESDY C P, KALANTAR-ZADEH K. Combined high serum ferritin and low iron saturation in hemodialysis patients:the role of inflammation[J]. Clin J Am Soc Nephrol, 2008, 3(6):1691-1701.
[22]
SPERB F, WERLANG I C, MARGIS-PINHEIRO M, et al. Molecular cloning and transgenic expression of a synthetic human erythropoietin gene in tobacco[J]. Appl Biochem Biotechnol, 2011, 165(2):652-665.
[23]
FUKUDA M H, SASAKI H, LOPEZ L, et al. Survival of recombinant erythropoietin in the circulation:the role of carbohydrates[J]. Blood, 1989,73(1):84-89.
[24]
CASADEVALL N, NATAF J, VIRON B, et al, Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin[J]. N Engl J Med, 2002,346(7):469-475.
[25]
MANENTI L, VAGLIO A. Pure red cell aplasia followed by disseminated intravascular coagulation in a haemodialysis patient receiving erythropoietin[J]. Nephrol Dial Transpl, 2007, 22(5):1465-1467.
[26]
LEKARSKI P M. Results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease[J]. Pol Merkur Lekarski,2010, 28(163):13-17.
[27]
WU Y W, BAUER L A, BALLARD R A, et al. Erythropoietin for neuroprotection in neonatal encephalopathy:safety and pharmacokinetics[J]. Pediatrics, 2012, 130(4):683-691.
2016, Vol. 51 
